Sunny Pharmtech Signs Development and Sales Agreement for Phytonadione Injectable with Middle Eastern Client
On May 13, Sunny Pharmtech officially signed a development and sales agreement with a Middle Eastern client for Phytonadione Injectable, targeting the vitamin deficiency and coagulation disorders. Following successful development and regulatory approval, the product is projected to capture the U.S. market, estimated at approximately USD 43 million. This collaboration highlights Sunny’s ongoing efforts to expand its international strategic partnerships, and broadens potential opportunities for drug licenses in other countries.
Sunny Pharmtech currently has an injectable product under review by the U.S. FDA. The newly signed agreement focuses on the pre-filled syringe (PFS) dosage form, which ensures precisely pre-filled with the drug and sterile sealing, enhancing both accuracy and safety.